Publications by authors named "Thomas Haehner"

Claim this Profile
A
A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma.
Torsten Diesinger, Alfred Lautwein, Sebastian Bergler, Dominik Buckert, Christian Renz, Thomas Haehner

Can J Gastroenterol Hepatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Ï
ω-Imidazolyl-alkyl derivatives as new preclinical drug candidates for treating non-alcoholic steatohepatitis.
Torsten Diesinger, Alfred Lautwein, Vyacheslav Buko, Elena Belonovskaya, Oksana Lukivskaya, Thomas Haehner

Physiol Rep· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.
Torsten Diesinger, Vyacheslav Buko, Alfred Lautwein, Radovan Dvorsky, Elena Belonovskaya, Thomas Haehner

PLoS One· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of cytochrome P450 mediated enzyme activity by alkylphosphocholines.
Thomas Haehner, Ulrich Massing, Torsten Diesinger, Dieter Müller-Enoch

Z Naturforsch C J Biosci· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system.
Thomas Haehner, Mohamed Osman I Refaie, Dieter Müller-Enoch

Arzneimittelforschung· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis